Intravaginal immunization using a novel antigen delivery device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses by McKay PF, Mann JF, Pattani A, Kett VL, Malcolm K, Shattock RJ

Optimising CN54gp140 plasmid delivery by comparing intramuscular and intradermal vaccination combinations with and without electroporation by Mann JF, McKay PF, Swales J, Klein K, Fiserova A, Cope A, Shattock RJ

P11-11. Stable lyophilised gel vehicles for vaginal administration of recombinant C-clade HIV-1 trimeric CN54gp140 by Shattock RJ, Woolfson AD, Malcolm RK, Andrews GP, Kett VL, Morrow RJ, Curran RM, Donnelly L

Antigen-specific T lymphocyte responses elicited by a DNA – MVA HIV CN54gp140 immunization regime are significantly altered by the TLR4 adjuvant GLA by McKay PF, Cope AV, Swales J, Joseph S, Esteban M, Tatoud R, Carter D, Weber J, Shattock RJ

P20-15. Evaluation of HIV-1 subtype B acute envelope-expressing infectious molecular clones by Arts EJ, Kappes JC, Krebs KC, Gao Y, Ochsenbauer-Jambor C, Fischetti L, Buffa V, King DF, Siddiqui AA, Shattock RJ

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice by Spencer, AJ, McKay, PF, Belij-Rammerstorfer, S, Ulaszewska, M, Bissett, CD, Hu, K, Samnuan, K, Blakney, AK, Wright, D, Sharpe, HR, Gilbride, C, Truby, A, Allen, ER, Gilbert, SC, Shattock, RJ, Lambe, T

An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial by Pollock, KM, Borges, AH, Cheeseman, HM, Rosenkrands, I, Schmidt, KL, Søndergaard, RE, Day, S, Evans, A, McFarlane, LR, Joypooranachandran, J, Amini, F, Skallerup, P, Dohn, RB, Jensen, CG, Olsen, AW, Bang, P, Cole, T, Schronce, J, Lemm, N-M, Kristiansen, MP, Andersen, PL, Dietrich, J, Shattock, RJ, Follmann, F